- Home
- AFCG vs TCRX Comparison
AFCG vs TCRX Comparison
Compare AFCG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFCG | TCRX |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.4M | 75.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AFCG | TCRX |
|---|---|---|
| Price | $3.06 | $1.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.50 | ★ $7.00 |
| AVG Volume (30 Days) | 280.8K | ★ 937.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.94% | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $24,563,601.00 | $10,325,000.00 |
| Revenue This Year | $1,334.03 | N/A |
| Revenue Next Year | $17.33 | $19.81 |
| P/E Ratio | $5.87 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $2.06 | $0.88 |
| 52 Week High | $5.78 | $2.57 |
Technical Indicators
Market Signals| Indicator | AFCG | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 38.45 |
| Support Level | $2.74 | $0.93 |
| Resistance Level | $3.42 | $1.21 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 46.78 | 1.52 |
Price Performance
Historical ComparisonAbout AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is an externally managed Maryland corporation that operates as a Business Development Company (BDC). The firm's primary operations involve originating, structuring, underwriting, and managing senior secured loans and other debt securities. Its investment portfolio includes loans to state law-compliant cannabis operators, ancillary cannabis businesses, and middle-market companies in other industries. These loans are typically secured by collateral such as real estate, equipment, cash flows, and license values.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.